Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (186)	11/15/1997 10:11:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 569

Competition This is a brief blurb about the sales force that will compete against the AHP sales force, if ANIK can get their version of Synvisc (OrthoVisc) passed by the FDA this qtr. ANIK just signed a $23.0 deal with BMY. FYI ------------ With the largest dedicated sales force addressing orthopaedic surgeons and related specialties, we believe Zimmer will provide powerful commercialization and distribution efforts to make ORTHOVISC the valued therapeutic option and preferred brand in the treatment of osteoarthritis, " said J. Melville Engle, president and chief executive officer of Anika. "Zimmer is the established world leader in knee replacement products and has a strong reputation with orthopaedic surgeons and musculoskeletal specialists around the globe." pnp1.individual.com Let's go AHP! Regards, John

To: John McCarthy who wrote (186)	11/16/1997 3:43:00 AM
From: ForYourEyesOnly	Read Replies (3) \| Respond to of 569

John, re: shorts, trends: As a one of the victims of the CYMI short attack, I have just started studying technical indicators so as to avoid going down with the ship again, or catching any more falling knives. Just from looking at some basic indicators for BIOX, 1. Looks like the price has moved below 21D and 50D MA. 2. MACD is now negative. 3. CCI is negative. 4. Stochastic is pointing down. 5. OBV is flat at a rather high level. I would love to hear your thoughts on these, particularly the OBV. Does OBV tend to move down last? Just from these, it seems to be in a negative trend. If the shorts push, they may have momentum on their side, right? I don't own this or ANIK now, but just from a price level and technical point of view, ANIK looks to be better positioned to move up in the short/mid term. Have you bought any ANIK yet? DEPO: As you know, DEPO made a big announcement recently, and the stock has not twitched. However, OBV is at a very high level, could this be telling us the stock is preparing to rocket up? Please let me know what you think. Good luck, and please do not take my comments as some attempt by a short to manipulate things. I am a NICE GUY. THC

To: John McCarthy who wrote (186)	11/16/1997 6:24:00 AM
From: James Baker	Read Replies (1) \| Respond to of 569

John, I am not so sure about the activity of shorts and what they can do to a stock. Yes they can "talk" it down by spreading reality or falsehoods. But my understanding is that you can sell short only after an UP TICK spceifically to prevent ever downward pressure by shorting. Yes it increases the pool of shares offered for sale. And I guess market makers can be market manipulators in the way they trade a stock. But look at CYMI in the last yr 5 to 45 stock price. The last 4 qt EPS are 0.13 0.15 0.24 0.23 First call estimates are for 97 0.83 and 98 1.06. This is ONLY a 35% growth rate and they were selling at 40X 1998 earnings est. I think that they got ahead of reality at 45 especially with the nice earnings at 0.24 but then on per share basis the next qt was actually lower. Add to this the Asian flu and that there business has more connection to the Asian market problems. I think that BIOX was ahead of itself at 41. I think that the recent action is forming a very strong base in the 32 - 33 range and this will be a very nice launching pad when Hylaform gets US approval and the revenue and earnings stream are established for Synvisc. I think BIOX has a great future and no shorting will keep this stock from recognizing it true potential in the future. Jim